33 recently arrived companies create hundreds of jobs
The efforts of BaselArea.swiss proved extremely successful in 2018. 33 companies – seven more than in the previous year – were persuaded to move to the Basel economic region. 16 companies arrived from Europe, nine of which came from Germany. BaselArea.swiss also supported six Swiss companies in the search for a suitable business location in the Basel region. Of the newly arrived companies, 19 operate in the life sciences and chemicals sectors.
Copyright: Basel Tourismus
The companies most recently relocated to the Basel economic region have already created 139 jobs and plan to add 296 more over the coming years. The huge interest in the Basel region as a business location was also reflected in the over 400 consultation sessions in Switzerland and abroad and the 69 visits to Basel made by investors and company delegations that were organised by BaselArea.swiss in 2018.
As well as promoting the location, BaselArea.swiss also achieved extremely impressive results in its second key activity: fostering innovation. 72 startups received support from BaselArea.swiss in founding their companies and the number of companies established increased by nine compared to the previous year. The startups were mainly companies operating in the life sciences and ICT sectors.
There was also a sharp rise in the demand for consulting and mentoring. Companies used this service provided by BaselArea.swiss 556 times, which represents a more than three-fold increase compared to the previous year. The events organised by BaselArea.swiss also proved extremely popular and provided around 6,000 participants with an opportunity for networking and generating new ideas.
See the press release here. The complete 2018 BaselArea.swiss annual report can be downloaded as a PDF.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More